NASDAQ NMS - GLOBAL MARKET · GLUE
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc

Biotechnology
$14.30
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
GLUE
Monte Rosa Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

39/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GLUE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GLUE catalysts
About Monte Rosa Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
173
Country
US

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$14.30
Last session
Day high
$14.30
Last session
Day low
$14.30
Last session
Previous close
$14.30
52W high
$25.31
-43.50% from high
52W low
$4.59
47% of range
Market cap
$1.2B
Beta
0.64
Shares out
85.3M
Avg volume
1.3M
VWAP
$14.30
Last session
Price history computed in-house
1W
-7.02%
1M
-37.23%
3M
-25.52%
1Y
+196.68%
YTD
-8.80%
SMA 50 $19.98 · below
SMA 200 $18.49 · below
52W position 47%

GLUE overview

Veridion Score
39
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GLUE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GLUE Form 4 filings
Public disclosures

Congress activity in GLUE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GLUE in the cached public ledger.

Federal contracts

GLUE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GLUE in this window.
Lobbying spend

GLUE lobbying filings, year to date.

Registered lobbying filings matched to Monte Rosa Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GLUE in this window.
Loading news for GLUE
Analyst ratings
Sovereign unlock shows live analyst consensus for GLUE.
Options
Sovereign unlock shows live options positioning for GLUE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.